Search

Your search keyword '"Naguib D"' showing total 3 results
Start Over Author "Naguib D" Publisher wiley-blackwell
3 results on '"Naguib D"'

1. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.

Author

Lazarian G, Theves F, Hormi M, Letestu R, Eclache V, Bidet A, Cornillet-Lefebvre P, Davi F, Delabesse E, Estienne MH, Etancelin P, Kosmider O, Laibe S, Lode L, Muller M, Nadal N, Naguib D, Pastoret C, Poulain S, Sujobert P, Veronese L, Imache S, Lefebvre V, Cymbalista F, Baran-Marszak F, and Soussi T

Subjects
Codon, Humans, Mutation, Chlorambucil therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Tumor Suppressor Protein p53 genetics
Published
2022
Full Text
View/download PDF

2. Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.

Author

Henry A, Bracquemart C, Naguib D, Chantepie S, Cheze S, and Johnson-Ansah HA

Subjects
Algorithms, Antineoplastic Agents therapeutic use, Basophils pathology, Dasatinib therapeutic use, Diagnosis, Differential, Fusion Proteins, bcr-abl genetics, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Leukemia, Myeloid, Acute genetics, Male, Middle Aged, Philadelphia Chromosome, Protein Kinase Inhibitors therapeutic use, Sarcoma, Myeloid etiology, Blast Crisis genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Mutation, Missense, Neoplasm Proteins genetics, Nucleophosmin genetics
Published
2021
Full Text
View/download PDF

3. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.

Author

Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, Bidet A, Bladé JS, Cayuela JM, Cony-Makhoul P, Cottin V, Delabesse E, Ebbo M, Fain O, Flandrin P, Galicier L, Godon C, Grardel N, Guffroy A, Hamidou M, Hunault M, Lengline E, Lhomme F, Lhermitte L, Machelart I, Mauvieux L, Mohr C, Mozicconacci MJ, Naguib D, Nicolini FE, Rey J, Rousselot P, Tavitian S, Terriou L, Lefèvre G, Preudhomme C, Kahn JE, and Groh M

Subjects
Adult, Disease-Free Survival, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Survival Rate, Tryptases blood, Vitamin B 12 blood, Adrenal Cortex Hormones administration & dosage, Eosinophilia blood, Eosinophilia drug therapy, Eosinophilia genetics, Eosinophilia mortality, Hematologic Neoplasms blood, Hematologic Neoplasms drug therapy, Hematologic Neoplasms genetics, Hematologic Neoplasms mortality, Myeloproliferative Disorders blood, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders genetics, Myeloproliferative Disorders mortality, Oncogene Proteins, Fusion blood, Oncogene Proteins, Fusion genetics, Receptor, Platelet-Derived Growth Factor alpha blood, Receptor, Platelet-Derived Growth Factor alpha genetics, mRNA Cleavage and Polyadenylation Factors blood, mRNA Cleavage and Polyadenylation Factors genetics
Abstract

FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in this retrospective nationwide study involving all French laboratories who perform the search of F/P fusion gene (study period: 2003-2019). The main organs involved included the spleen (44%), skin (32%), lungs (30%), heart (19%) and central nervous system (9%). Serum vitamin B12 and tryptase levels were elevated in 74/79 (94%) and 45/57 (79%) patients, respectively, and none of the 31 patients initially treated with corticosteroids achieved complete hematologic remission. All 148 (98%) IM-treated patients achieved complete hematologic and molecular (when tested, n = 84) responses. Forty-six patients eventually discontinued IM, among whom 20 (57%) relapsed. In multivariate analysis, time to IM initiation (continuous HR: 1,01 [0.99-1,03]; P = .05) and duration of IM treatment (continuous HR: 0,97 [0,95-0,99]; P = .004) were independent factors of relapse after discontinuation of IM. After a mean follow-up of 80 (56) months, the 1, 5- and 10-year overall survival rates in IM-treated patients were 99%, 95% and 84% respectively. In F/P+ MN-eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM., (© 2020 Wiley Periodicals LLC.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results